A stronger foundation for confident target selection.
Most drug candidates never make it to market, and poor target selection is behind the majority of those failures. This webinar looks at whether single-cell RNA sequencing, already a mainstay in academic research, can close that gap and give drug discovery teams the stronger, more complete foundation they need before making costly downstream commitments.
Why watch this video?
- Build more confidence in target selection, one of the biggest predictors of whether a program ultimately succeeds
- See how a fuller cellular picture can sharpen biomarker strategy across the development process, not just at the start
- Understand what's really holding broader single cell adoption back in pharma today, and what's changing
- Get a forward-looking view of where single cell fits into tomorrow's drug development programs
